Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Update

Tempest Therapeutics, Inc. (NASDAQ:TPST) saw a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 205,707 shares, a decrease of 39.7% from the May 31st total of 341,334 shares. Currently, 2.2% of the shares of the stock are short sold. Based on an average trading volume of 100,848 shares, the short-interest ratio is currently 2.0 days.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on TPST shares. Wall Street Zen lowered shares of Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Zacks Research lowered shares of Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Reduce”.

Tempest Therapeutics Trading Down 1.8%

TPST traded down $0.02 on Thursday, hitting $1.09. 81,467 shares of the company’s stock were exchanged, compared to its average volume of 168,382. Tempest Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $12.23. The stock has a market cap of $17.42 million, a price-to-earnings ratio of -0.18 and a beta of -1.73. The firm has a 50-day moving average price of $1.56 and a 200-day moving average price of $2.12.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($2.25). On average, equities analysts predict that Tempest Therapeutics will post -1.34 EPS for the current year.

Institutional Investors Weigh In On Tempest Therapeutics

Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP acquired a new position in Tempest Therapeutics during the fourth quarter worth $33,000. Vanguard Group Inc. increased its stake in shares of Tempest Therapeutics by 20.8% in the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after acquiring an additional 27,952 shares during the last quarter. Finally, Sabby Management LLC acquired a new stake in shares of Tempest Therapeutics in the 4th quarter worth $513,000. 22.52% of the stock is currently owned by hedge funds and other institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.